Otsuka has claimed a significant victory in the increasingly competitive immunoglobulin A nephropathy (IgAN) field with FDA accelerated approval of Voyxact, the first-in-class anti-APRIL biologic therapy designed to treat this serious kidney disorder, as reported by Fierce Pharma.
A Novel Mechanism Addresses Unmet Need
Voyxact, also known as sibeprenlimab, works by blocking A proliferation-inducing ligand (APRIL), a protein that drives autoantibody production, triggering the inflammation and kidney damage characteristic of IgAN. Administered as a once-monthly self-injected therapy, the drug represents a mechanistic shift in IgAN treatment, it is the first biologic drug approved for the disease, whereas all four earlier FDA approvals for IgAN went to small-molecule compounds.
Compelling Clinical Evidence
The approval was supported by Phase 3 data from the Visionary trial, which demonstrated robust efficacy. Voyxact achieved a 51% placebo-adjusted reduction in proteinuria, protein in the urine, at nine months of treatment. By one year, this improvement increased to a 54.3% placebo-adjusted reduction. Importantly, enrolled patients were already receiving standard-of-care therapies including ACE inhibitors, angiotensin II receptor blockers, and/or SGLT2 inhibitors, making Voyxact’s independent contribution particularly noteworthy.
Broad Patient Eligibility
Unlike some competitors, the FDA imposed no restrictions based on specific urinary protein-to-creatinine ratio (UPCR) thresholds. This contrasts with Novartis’ recently approved Vanrafia, which is limited to patients with UPCR of at least 1.5 g/g. This broader eligibility could provide Voyxact with competitive advantages in real-world clinical practice.
Path to Full Approval
The accelerated approval comes with conditions. Otsuka must demonstrate whether Voyxact can slow disease progression—measured by estimated glomerular filtration rate (eGFR) decline, over two years in the ongoing Visionary study. The company expects these results in early 2026, potentially paving the way for traditional FDA approval and expanded therapeutic claims.
An Intensifying Competitive Landscape
Voyxact’s approval signals confidence in the APRIL inhibitor approach, but Otsuka faces formidable competition. Multiple pharmaceutical companies are pursuing anti-APRIL strategies, while others are developing dual BAFF/APRIL inhibitors that target additional mechanisms in autoantibody production.
Vertex is advancing povetacicept, a BAFF/APRIL inhibitor acquired through its $4.9 billion takeover of Alpine Immune Sciences. Phase 2 data showed 64% absolute proteinuria reductions, with an FDA application expected this year and potential approval by end of 2026.
Vera Therapeutics is developing atacicept, another BAFF/APRIL dual inhibitor, which demonstrated a 42% UPCR reduction in interim Phase 3 analysis. Novartis has multiple shots on goal with Vanrafia, Fabhalta, and the anti-APRIL compound zigakibart, while RemeGen’s telitacicept showed positive Phase 3 results in China.
